Synedica Retatrutide 40mg Pen
$250.00 Original price was: $250.00.$230.00Current price is: $230.00.
Synedica Retatrutide 40mg Pen uk– Triple Agonist Peptide for Weight Loss
buy Synedica Retatrutide 40mg pen– is an advanced tri-agonist peptide that targets GLP-1, GIP, and glucagon receptors simultaneously. This powerful compound is designed for research into next-generation weight loss, energy balance, and metabolic optimization,Backed by Synedica’s reputation for pharmaceutical-grade innovation, this 40mg formulation is ideal for studies involving multi-pathway appetite regulation, improved insulin signaling, and fat oxidation. it shows significant potential in reducing body fat and improving insulin sensitivity
Key Features:
- Triple receptor agonist: GLP-1, GIP, and Glucagon
- 40mg per vial – potent and long-acting
- Synedica-grade peptide quality
- Ideal for cutting-edge obesity and diabetes research
How to Use Synedica Retatutide:
Form: Injectable peptide
Dosage: Start with 0.5 mg per week, gradually increase to 3-4 mg per week as tolerated.
Cycle Length: Typically 8–16 weeks; take a 4-week break after each cycle
Administration: Subcutaneous injection, once a week
How It Works:
- GLP-1 Agonism: Reduces appetite and helps control blood sugar levels.
- GIP Agonism: Supports insulin release and boosts metabolic efficiency.
- Glucagon Activation: Increases energy expenditure and fat breakdown.
By targeting these three pathways, Synedica Retatutide offers more effective fat loss and metabolic benefits than traditional peptides like semaglutide or liraglutide.
Recommended Stacks:
Synedica Semaglutide (low dose) for additional appetite control
Viogen Semaglutide or Hyge Semaglutide for post-cycle maintenance
Tirzepatide-based products (like VLS or Synedica Tirzepatide) for a gradual transition after the cycle
Related products
-
Synedica Semaglutide 8mg Pen
$210.00Original price was: $210.00.$175.00Current price is: $175.00.Add to cartSynedica Semaglutide 8mg Pen – High-Purity GLP-1 Weight Loss Formula Synedica Semaglutide 8mg pen– is a potent GLP-1 receptor agonist designed to improve insulin sensitivity, reduce appetite, and promote fat loss. As one of the top fat loss peptides for 2025, it’s widely used for both weight loss and managing type 2 diabetes. Semaglutide works …
-
Buy alluvi retatrutide 40mg uk
$385.00 – $1,500.00Price range: $385.00 through $1,500.00Rated 5.00 out of 5Select options This product has multiple variants. The options may be chosen on the product pageIf you’re looking to buy Retatrutide, DN Research offers the highest-quality peptides with over 99% purity. Produced in European, GMP state-of-the-art laboratories, our peptides are trusted for scientific research and development.
✓ Fast Delivery
✓ Premium Quality
✓ 3rd Party TestedProduct Name: Retatrutide
Form: Prefilled injectable pen
Dosage: 10 mg per dose
Quantity: 4 doses per pen (4 × 10 mg)
Usage: 1 subcutaneous injection per week
Indication: Supports weight loss / obesity treatment
Mode of Action: Triple agonist (GLP-1, GIP, Glucagon)
Manufacturer: Eli Lilly and Company
Country of Origin: United States
Included Accessories: Sterile needles + user manual
Storage: Keep refrigerated (2–8 °C) -
Buy Ozempic online overnight delivery
$120.00 – $290.00Price range: $120.00 through $290.00Select options This product has multiple variants. The options may be chosen on the product pageour minimum order 2pens
Shipping: Overnight Delivery Available
Origin: USA-Discreet & Worldwide Shipping
100% Anonymity And No Prescription Required
-
VLS Retatrutide 20mg Pen
$180.00Original price was: $180.00.$160.00Current price is: $160.00.Add to cartVLS Retatrutide – Balanced GLP-1/GIP/Glucagon Trifecta for Fat Loss VLS Retatrutide 20mg Pen is a potent trifecta agonist targeting GLP-1, GIP, and Glucagon receptors. Manufactured by Vitality Life Science (VLS), this innovative peptide pen is engineered for advanced research into metabolic enhancement, fat burning, and glycemic regulation. With a 20mg concentration delivered via a precision pen, …






Reviews
There are no reviews yet.